RxDoctor Payments Data

Julie Harris

Nurse Practitioner · Marianna, FLNPI 1568502805

Payments from drug & device makers

$1,075in general payments, 2019–2025

Across 66 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$863
  • Inari Medical, Inc.$139
  • Idorsia Pharmaceuticals US Inc$22
  • Eisai Inc.$19
  • AbbVie$19
  • Astellas Pharma US Inc$13

What the payments were for

  • Food & beverage$1,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,075 in reported general payments places this provider in the 75th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$1,347
Medicare patients
16
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$165,567
OzempicSemaglutide120$155,044
FarxigaDapagliflozin Propanediol92$79,332
JanuviaSitagliptin Phosphate58$54,485
MounjaroTirzepatide19$35,659
JardianceEmpagliflozin20$31,148
Tresiba Flextouch U-100Insulin Degludec32$28,136
ProliaDenosumab13$23,340
XareltoRivaroxaban34$22,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,561
SymbicortBudesonide/Formoterol Fumarate37$17,517
LinzessLinaclotide17$16,551
JanumetSitagliptin Phos/Metformin Hcl25$15,312
Tresiba Flextouch U-200Insulin Degludec22$13,803
NexletolBempedoic Acid13$11,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$863$155,044120 claims
AbbVieLinzess$19$16,55117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Marianna

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →